A Phase II Study of Dasatinib to Treat Recurrent Clear Cell Cancer of the Ovaries or Endometrium

Full Title
A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #120636) In Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression (GOG-0283)

Five percent of gynecologic cancers are clear cell cancers. About half of clear cell cancers affecting the ovaries or endometrium (uterine lining) have a faulty version of a protein called BAF250a. Normal BAF250a keeps healthy cells from becoming cancer cells. BAF250s that does not function well may lead to cancer growth.

Laboratory studies have shown that dasatinib is effective against ovarian and endometrial cancer cells that have an altered version of the BAF250a protein. In this Gynecologic Oncology Group study, researchers are evaluating the safety and effectiveness of dasatinib in women with clear cell cancer of the ovaries, fallopian tubes, peritoneum, or endometrium whose cancer has persisted or returned despite standard therapy.

Dasatinib is already approved for treating a type of leukemia; its use in this study is considered investigational. It is a pill that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have clear cell cancer of the ovaries, fallopian tubes, peritoneum, or endometrium that has persisted or returned despite standard therapy.
  • Patients may have had up to three prior regimens of chemotherapy, with at least one of them including a platinum-containing drug.
  • At least 3 weeks must have passed since completion of prior chemotherapy or radiation therapy and entry into the study.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. David Hyman at 646-888-4544.

Ovarian Cancer
Uterine (Endometrial) Cancer
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »